Resources from the same session
LBA1 - Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence
Presenter: Masahiro Tsuboi
Session: Presidential Symposium I
Resources:
Abstract
Slides
Webcast
LBA2 - Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study
Presenter: Benjamin Solomon
Session: Presidential Symposium I
Resources:
Abstract
Slides
Webcast
696O_PR - Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial
Presenter: Toni Choueiri
Session: Presidential Symposium I
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA1
Presenter: Johan Vansteenkiste
Session: Presidential Symposium I
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Solange Peters
Session: Presidential Symposium I
Resources:
Webcast
Q&A and live discussion
Presenter: Solange Peters
Session: Presidential Symposium I
Resources:
Webcast
Invited Discussant 696O_PR
Presenter: Camillo Guglielmo Porta
Session: Presidential Symposium I
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Solange Peters
Session: Presidential Symposium I
Resources:
Webcast